- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Eugene Science Inc. (OTCBB: EUSI), a leader in the nutraceutical marketplace with its cholesterol lowering CholZero (CZ™) plant sterols, today announced it has engaged the prestigious Korea Research Institute of Bioscience and Biotechnology (KRIBB) to advance the production level of the Company's patented microorganism-based AD/ADD processing biotechnology to commercial scale.
AD/ADD is a key ingredient of steroid hormone medical products such as androgens, estrogens, gestogens, gluco-corticoids, and mineral-corticoids -- and Eugene Science's AD/ADD processing biotechnology is currently well established for manufacturing product at the prototype scale. The Company's process produces significantly higher conversion rates of plant sterols into AD/ADD when compared with conventional chemical synthesis as well as being substantially more cost-effective and environmentally friendly.
"Our AD/ADD microbial conversion production process is vastly superior to existing conventional processes for efficiency and purity," said Seung Kwon Noh, Eugene Science Chairman and Chief Executive Officer. "We use a simpler purification process that enables a greater conversion of sterol to AD/ADD that is only possible with our patented nanotechnology for converting non-soluble sterols into water dispersible sterols. Eugene Science's technology also reduces the cost of production by broadening the limited spectrum of raw materials that can be used to produce AD/ADD from sitosterol only, in conventional processes, to all kinds of plant sterols with our process."
Eugene Science has entered discussions with the leading AD/ADD pharmaceutical producers to market the Company's patented technology, which must be proven to scale efficiently at the one-ton production level to be suitable for commercial applications. The Company expects a formal interim KRIBB report on the AD/ADD processing scale project by the second quarter of 2008, with a final report due in mid 2008.
AD/ADD is a key ingredient for most steroid hormone medical products that have been extensively used in treating arthritis, neuralgia, sterility as well as for contraception and hormone replacement therapy (HRT). Examples of such products include Testoviron®, a testosterone injection manufactured by Schering-Plough, and Depo-subQ Provera 104™, an injectable contraceptive manufactured by Pfizer. The annual market size of AD/ADD itself is estimated at approximately $1 billion and is expected to grow with its expanded use as a dietary supplement to help the regulation of body metabolisms and improvement of sexual performances.
Eugene Science holds AD/ADD production process patents granted to the Company in Korea. International patents have also been applied for in the U.S., Japan and China. Additionally, China has granted the Company a patent on its AD/ADD microorganism catalyst, with patent applications pending in the U.S. and Japan.
KRIBB is Korea's largest and leading biotechnology research center. In support of its biotech industry, the Korean Government is also providing the AD/ADD scaling project with financial support.
The chemical name for AD is 4-Androstene-3,17-dione, and for ADD is 1,4-Androstadiene-3,17-dione. They are both steroid hormone intermediates, used in regulating physiological metabolism, improving sexual performance and as ingredients or base substances for other medical formulas. AD/ADD has been produced by both chemical synthesis and bioconversion using micro-organisms with animal or plant sterols and their derivatives.
To be added to Eugene Science's investor lists, please contact Zachary Bryant at or at 818-382-9718.
About Eugene Science Inc.
Based in Seoul, Korea, Eugene Science is a global biotechnology company tackling ailments such as heart disease, obesity and diabetes through innovation in the nutraceutical field. Its first commercial heart disease product, CZ™, is a patented, nanoscience-based, water-dispersible functional food ingredient containing natural plant sterols that help maintain healthy cholesterol levels by inhibiting its absorption. CZ™ is available in capsule form, or as a food or beverage additive. These plant sterols are approved by the U.S. FDA for health claims related to cholesterol lowering efficacy. Please visit www.eugene21.com.
Forward-Looking Statements: This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition, from time to time, Eugene Science, or its representatives, have made or may make forward-looking statements, orally or in writing. The words "estimate," "project," "potential," "intended," "expect," "anticipate," "believe" and similar expressions or words are intended to identify forward-looking statements. Such forward-looking statements may be included in, but are not limited to, various filings made by Eugene Science with the United States Securities and Exchange Commission (available at www.sec.gov), press releases or oral statements made with the approval of an authorized executive officer of Eugene Science. Actual results could differ materially from those projected or suggested in any forward-looking statements as a result of a wide variety of factors and conditions. Reference is hereby made to Eugene Science's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2006 for information regarding those factors and conditions. Among the important factors that could cause actual results to differ materially from management's projections, estimates and expectations include, but are not limited to: changing economic influences in the nutraceutical industry; dependence on key personnel; actions of third parties; the market for nutraceutical products containing Eugene Science's CZ™ ingredient, the Company's ability to develop and market its AD/ADD production process; and availability of adequate financing. Readers are cautioned not to place undue reliance upon these forward-looking statements that speak only as of the date of this press release. Eugene Science undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.
For more information, please click here
Investor Relations International
Senior Vice President and Account Group Manager
Company Contact for AD/ADD and CZ™
U.S. Headquarters (Los Angeles)
Copyright © MarketwireIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
PCATDES Starts Field Testing of Photocatalytic Reactors in South East Asia December 28th, 2016